{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:43:10Z","timestamp":1793090590014,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Macrolide resistance was found in 39.5% of 3626 nonduplicate Streptococcus pneumoniae isolates from adult ambulatory and inpatient settings at 329 US hospitals (2018\u20132019). Macrolide resistance was significantly higher for respiratory vs blood isolates and ambulatory vs inpatient settings. Despite geographic variation, S. pneumoniae macrolide resistance was &amp;gt;25% in most regions.<\/jats:p>","DOI":"10.1093\/ofid\/ofab063","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T09:51:58Z","timestamp":1612518718000},"source":"Crossref","is-referenced-by-count":43,"title":["A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant\n                    <i>S. pneumoniae<\/i>\n                    in Ambulatory and Hospitalized Adult Patients in the United States"],"prefix":"10.1093","volume":"8","author":[{"given":"Vikas","family":"Gupta","sequence":"first","affiliation":[{"name":"Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalvin C","family":"Yu","sequence":"additional","affiliation":[{"name":"Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schranz","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P","family":"Gelone","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"2021083112114222900_CIT0001","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fimmu.2018.01366","article-title":"Streptococcus pneumoniae\u2019s virulence and host immunity: aging, diagnostics, and prevention","volume":"9","author":"Brooks","year":"2018","journal-title":"Front Immunol"},{"key":"2021083112114222900_CIT0002","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infection in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Lower Respiratory Infections Collaborators","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021083112114222900_CIT0003","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJMoa1209165","article-title":"U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination","volume":"369","author":"Griffin","year":"2013","journal-title":"N Engl J Med"},{"key":"2021083112114222900_CIT0004","doi-asserted-by":"crossref","first-page":"12896","DOI":"10.1073\/pnas.1721095115","article-title":"Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects","volume":"115","author":"Klugman","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021083112114222900_CIT0005","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2019.15468","article-title":"Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia. The LEAP 2 randomized clinical trial","volume":"322","author":"Alexander","year":"2019","journal-title":"JAMA"},{"key":"2021083112114222900_CIT0006","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10096-020-03870-3","article-title":"Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study","volume":"39","author":"Carugati","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2021083112114222900_CIT0007","author":"US Department of Health and Human Services"},{"key":"2021083112114222900_CIT0008"},{"key":"2021083112114222900_CIT0009","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021083112114222900_CIT0010","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMra1312885","article-title":"Community-acquired pneumonia","volume":"371","author":"Musher","year":"2014","journal-title":"N Engl J Med"},{"key":"2021083112114222900_CIT0011","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2021083112114222900_CIT0012","author":"Centers for Disease Control and Prevention"},{"key":"2021083112114222900_CIT0013","author":"Centers for Disease Control and Prevention","year":"2018"},{"key":"2021083112114222900_CIT0014","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/670621","article-title":"Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study","volume":"34","author":"Tabak","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021083112114222900_CIT0015","doi-asserted-by":"crossref","first-page":"ofy241","DOI":"10.1093\/ofid\/ofy241","article-title":"Carbapenem-nonsusceptible gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study","volume":"5","author":"McCann","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021083112114222900_CIT0016","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1017\/ice.2019.236","article-title":"Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: retrospective analysis of 2016\u20132017 data from US hospitals","volume":"40","author":"Tabak","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021083112114222900_CIT0017","article-title":"Antibiotic susceptibility of Streptococcus pneumoniae in the US in 2014","author":"Keedy"},{"issue":"Suppl 1","key":"2021083112114222900_CIT0018","first-page":"S14\u201322","article-title":"Antimicrobial susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific region: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997\u20132016)","volume":"6","author":"Sader","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021083112114222900_CIT0019","doi-asserted-by":"crossref","first-page":"e01555-17","DOI":"10.1128\/AAC.01555-17","article-title":"In vitro activities of ceftaroline and comparators against Streptococcus pneumoniae isolates from U.S. hospitals: results from seven years of the AWARE surveillance program (2010 to 2016)","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021083112114222900_CIT0020","doi-asserted-by":"crossref","first-page":"ofaa065","DOI":"10.1093\/ofid\/ofaa065","article-title":"Antibiotic treatment failure and associated outcomes among adult patients with community-acquired pneumonia in the outpatient setting: a real-world US insurance claims database study","volume":"7","author":"Tillotson","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2021083112114222900_CIT0021","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3201\/eid1508.081187","article-title":"Increase in pneumococcus macrolide resistance, United States","volume":"15","author":"Jenkins","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"Suppl 4","key":"2021083112114222900_CIT0022","first-page":"iv39\u201347","article-title":"Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007\u201316","volume":"74","author":"Golden","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021083112114222900_CIT0023","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/cid\/ciz1049","article-title":"Blood cultures versus respiratory cultures: 2 different views of pneumonia","volume":"71","author":"Haessler","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021083112114222900_CIT0024","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1086\/386548","article-title":"Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups\/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia","volume":"189","author":"Buie","year":"2004","journal-title":"J Infect Dis"},{"key":"2021083112114222900_CIT0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","article-title":"Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis","volume":"24","author":"van Aalst","year":"2018","journal-title":"Travel Med Infect Dis"},{"key":"2021083112114222900_CIT0026","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.2020.9184","article-title":"Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States","volume":"323","author":"Vaduganathan","year":"2020","journal-title":"JAMA"},{"key":"2021083112114222900_CIT0027","doi-asserted-by":"crossref","first-page":"e1001598","DOI":"10.1371\/journal.pmed.1001598","article-title":"Molecular diagnostics for gonorrhoea: implications for antimicrobial resistance and the threat of untreatable gonorrhoea","volume":"11","author":"Low","year":"2014","journal-title":"PLoS Med"},{"key":"2021083112114222900_CIT0028","doi-asserted-by":"crossref","first-page":"e01125-19","DOI":"10.1128\/JCM.01125-19","article-title":"Molecular testing for Mycoplasma genitalium in the United States: results from the AMES prospective multicenter clinical study","volume":"57","author":"Gaydos","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2021083112114222900_CIT0029","first-page":"103","article-title":"CDC Grand Rounds: the growing threat of multidrug-resistant gonorrhea","volume":"62","author":"Hook","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021083112114222900_CIT0030","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/cid\/ciaa157","article-title":"Rising pneumococcal antibiotic resistance in the post 13-valent pneumococcal conjugate vaccine era in pediatric isolates from a primary care setting","volume":"72","author":"Kaur","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2021083112114222900_CIT0031","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/INF.0000000000002549","article-title":"Invasive Streptococcus pneumoniae infections and vaccine failures in children in Ireland from the postvaccine era from 2007 to 2018","volume":"39","author":"Corcoran","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2021083112114222900_CIT0032","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cmi.2019.10.034","article-title":"Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain","volume":"26","author":"Gonz\u00e1lez-D\u00edaz","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2021083112114222900_CIT0033","article-title":"Adverse effects of fluoroquinolones: where do we stand now?","author":"Sakoulas","journal-title":"NEJM Journal Watch"},{"key":"2021083112114222900_CIT0034","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/QCO.0000000000000526","article-title":"New antibiotics for community-acquired pneumonia","volume":"32","author":"Kollef","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"2021083112114222900_CIT0035","author":"The Joint Commission","year":"2019"},{"key":"2021083112114222900_CIT0036","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/jama.2016.4151","article-title":"Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010\u20132011","volume":"315","author":"Fleming-Dutra","year":"2016","journal-title":"JAMA"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab063\/36196427\/ofab063.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/7\/ofab063\/40141263\/ofab063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/7\/ofab063\/40141263\/ofab063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T08:16:21Z","timestamp":1630397781000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab063\/6128791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab063","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,2,4]]},"article-number":"ofab063"}}